Silence Therapeutics Plc (SLNCF)
3.85
-0.15
(-3.75%)
USD |
OTCM |
Oct 09, 16:00
Silence Therapeutics Cash from Operations (Quarterly) : 1.548M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.548M |
| March 31, 2026 | -15.60M |
| December 31, 2025 | -16.66M |
| September 30, 2025 | -11.07M |
| June 30, 2025 | -22.79M |
| March 31, 2025 | -12.31M |
| September 30, 2024 | -24.95M |
| June 30, 2024 | -5.298M |
| March 31, 2024 | -9.143M |
| Date | Value |
|---|---|
| December 31, 2023 | -14.25M |
| September 30, 2023 | -5.474M |
| June 30, 2023 | -18.89M |
| March 31, 2023 | -9.107M |
| December 31, 2022 | -15.71M |
| September 30, 2022 | -11.05M |
| June 30, 2022 | -10.37M |
| March 31, 2022 | -19.28M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -2.571M |
| Mereo BioPharma Group Plc | -6.048M |
| Compass Pathways Plc | -40.37M |
| HemoGenyx Pharmaceuticals Plc | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 64.78M |
| Cash from Financing (Quarterly) | 0.002M |
| Free Cash Flow | -41.79M |
| Free Cash Flow Per Share (Quarterly) | 0.0109 |
| Free Cash Flow to Equity (Quarterly) | 1.572M |
| Free Cash Flow to Firm (Quarterly) | 1.548M |
| Free Cash Flow Yield | -7.66% |